PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
The Korean Journal of Internal Medicine10.3904/kjim.2018.179201934150-59Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancerSung Won Lim, Myung-Ju Ahnhttp://kjim.org/upload/kjim-2018-179.pdf, http://kjim.org/journal/view.php?doi=10.3904/kjim.2018.179, http://kjim.org/upload/kjim-2018-179.pdf
Cancer Medicine10.1002/cam4.8192016592567-2578Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerAngel Qin, David G. Coffey, Edus H. Warren, Nithya Ramnathhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcam4.819, https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.819
Current Treatment Options in Oncology10.1007/s11864-018-0556-72018198Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung CancerSonam Puri, Michael Shafique, Jhanelle E. Grayhttp://link.springer.com/article/10.1007/s11864-018-0556-7/fulltext.html, http://link.springer.com/content/pdf/10.1007/s11864-018-0556-7.pdf, http://link.springer.com/content/pdf/10.1007/s11864-018-0556-7.pdf
Cancer Treatment Reviews10.1016/j.ctrv.2018.02.00220186421-29Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questionsJ. Remon, N. Vilariño, N. Reguarthttps://api.elsevier.com/content/article/PII:S0305737218300124?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0305737218300124?httpAccept=text/plain
Respirology10.1111/resp.13420_553201823289-289THE SUM OF TUMOR SIZE PREDICTS THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN NON-SMALL CELL LUNG CANCERhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fresp.13420_553, http://onlinelibrary.wiley.com/wol1/doi/10.1111/resp.13420_553/fullpdf
Annals of Oncology10.1093/annonc/mdz1852019EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancerM Früh, S Petershttp://academic.oup.com/annonc/advance-article-pdf/doi/10.1093/annonc/mdz185/28885062/mdz185.pdf
Clinical Lung Cancer10.1016/j.cllc.2017.02.0012017185444-459.e1Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic ReviewPeter M. Ellis, Emily T. Vella, Yee C. Unghttps://api.elsevier.com/content/article/PII:S1525730417300438?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730417300438?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2016.06.01620169979-87Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancerKazuhiko Shien, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistubahttps://api.elsevier.com/content/article/PII:S0169500216303749?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500216303749?httpAccept=text/plain
Lung Cancer10.1016/j.lungcan.2017.11.007201811780Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75]J. Remon, N. Pardo, A. Martinez-Martí, S. Cedrés, A. Navarro, A.M. Martinez de Castro, E. Feliphttps://api.elsevier.com/content/article/PII:S0169500217305640?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0169500217305640?httpAccept=text/plain
BioDrugs10.1007/s40259-019-00339-42019332159-171First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint InhibitorsOlivier Bylicki, Helene Barazzutti, Nicolas Paleiron, Jacques Margery, Jean-Baptiste Assié, Christos Chouaïdhttp://link.springer.com/content/pdf/10.1007/s40259-019-00339-4.pdf, http://link.springer.com/article/10.1007/s40259-019-00339-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40259-019-00339-4.pdf